NCT05613413 2026-01-08
LUNG-IST-127
University of Illinois at Chicago
Phase 2 Recruiting
Clinical Trials
3 trialsNCT06026410 2026-01-02
FIT-001
Kura Oncology, Inc.
Phase 1 Recruiting
NCT01639508 2025-12-17
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting